The FDA has determined that the nationwide shortage of semaglutide injection, used for both diabetes and weight loss, is resolved after more than two years of limited availability due to high demand.

The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive changes.

Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...